Display options
Cite
Liu L, Zhou XM, Yang FF, et al. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer. Oncotarget. 2017;8(37):62069-62080doi: 10.18632/oncotarget.18911.
Liu, L., Zhou, X. M., Yang, F. F., Miao, Y., Yin, Y., Hu, X. J., Hou, G., Wang, Q. Y., & Kang, J. (2017). TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer. Oncotarget, 8(37), 62069-62080. https://doi.org/10.18632/oncotarget.18911
Liu, Li, et al. "TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer." Oncotarget vol. 8,37 (2017): 62069-62080. doi: https://doi.org/10.18632/oncotarget.18911
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu XJ, Hou G, Wang QY, Kang J. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer. Oncotarget. 2017 Jul 01;8(37):62069-62080. doi: 10.18632/oncotarget.18911. eCollection 2017 Sep 22. PMID: 28977927; PMCID: PMC5617487.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 01;8(37):62069-62080. doi: 10.18632/oncotarget.18911. eCollection 2017 Sep 22.

TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.

Oncotarget

Li Liu, Xiao-Ming Zhou, Fang-Fei Yang, Yuan Miao, Yan Yin, Xue-Jun Hu, Gang Hou, Qiu-Yue Wang, Jian Kang

Affiliations

  1. Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China.
  2. Department of Respiratory Medicine, The Shengjing Hospital of China Medical University, Shenyang 110004, China.
  3. Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang 110001, China.

PMID: 28977927 PMCID: PMC5617487 DOI: 10.18632/oncotarget.18911

Abstract

Expression pattern and biological roles of TRIM22 remains unknown in most human cancers. The present study aims to discover its clinical significance and function in human non-small cell lung cancer (NSCLC). Immunohistochemistry was used to examine TRIM22 expression in 126 cases of NSCLC specimens. TRIM22 protein was upregulated in 70/126 (55.6%) non-small cell lung cancer tissues compared with normal lung tissue. TRIM22 overexpression was associated with advanced TNM stage, positive nodal metastasis and poor prognosis. Plasmid and siRNA transfection were performed in lung cancer cell lines. TRIM22 overexpression promoted proliferation, colony formation and invasion in A549 cells. While its depletion exhibited the opposite effects in H1299 cell line. TRIM22 overexpression promoted cell cycle progression through regulation of cyclin D1, cyclin E and p27. TRIM22 also changed the expression of epithelial to mesenchymal transition (EMT) markers including E-cadherin N-cadherin, Vimentin and Snail. Furthermore, TRIM22 activated PI3K/AKT/GSK3β/β-catenin oncogenic signaling pathways. Treatment with PI3K inhibitor LY294002 and β-catenin siRNA blocked the effects of TRIM22 on EMT in TRIM22-overexpressing cells. In conclusion,TRIM22 serves as an important oncoprotein and a promoter of cell proliferation and invasion through AKT/ GSK3β/β-catenin induced EMT in NSCLC.

Keywords: TRIM22; invasion; non-small cell lung cancer; prognosis; proliferation

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

References

  1. Carcinogenesis. 2012 Sep;33(9):1726-35 - PubMed
  2. J Microbiol. 2015 Jan;53(1):77-83 - PubMed
  3. Respiration. 2015 ;90(1):47-55 - PubMed
  4. Oncotarget. 2016 May 3;7(18):25366-76 - PubMed
  5. Nat Rev Cancer. 2009 Apr;9(4):265-73 - PubMed
  6. J Thorac Dis. 2015 May;7(5):850-60 - PubMed
  7. Respiration. 2016;91(3):235-40 - PubMed
  8. BMC Cancer. 2015 Aug 15;15:590 - PubMed
  9. Respiration. 2015;90(5):426-9 - PubMed
  10. Respiration. 2015;89(6):550-7 - PubMed
  11. PLoS One. 2015 Nov 24;10(11):e0142596 - PubMed
  12. Turk J Med Sci. 2015;45(4):865-71 - PubMed
  13. Curr Med Chem. 2013;20(33):4142-4152 - PubMed
  14. Biochem Biophys Res Commun. 2008 Sep 26;374(3):502-6 - PubMed
  15. Acta Pharm. 2015 Dec;65(4):463-71 - PubMed
  16. Clin Cancer Res. 2016 Apr 1;22(7):1674-1686 - PubMed
  17. Nat Cell Biol. 2011 Jun;13(6):728-33 - PubMed
  18. PLoS One. 2013;8(2):e56664 - PubMed
  19. Eur J Cancer. 2013 Dec;49(18):3900-13 - PubMed
  20. Mol Cell Biol. 2012 Oct;32(19):3903-12 - PubMed
  21. J Thorac Dis. 2015 Jul;7(7):1205-12 - PubMed
  22. J Steroid Biochem Mol Biol. 2015 Nov;154:217-25 - PubMed
  23. Pathol Res Pract. 2015 Aug;211(8):557-69 - PubMed
  24. Med Oncol. 2015 Jan;32(1):439 - PubMed
  25. J Thorac Dis. 2015 Apr;7(4):672-9 - PubMed
  26. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  27. J Diabetes Investig. 2016 Jan;7(1):27-8 - PubMed
  28. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  29. J Cell Physiol. 2015 Mar;230(3):504-9 - PubMed
  30. CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71 - PubMed
  31. Oncogene. 2007 Nov 22;26(53):7445-56 - PubMed
  32. Mol Biol Cell. 2007 Aug;18(8):3214-23 - PubMed
  33. Cell Death Dis. 2015 Jun 25;6:e1795 - PubMed
  34. Biochem Biophys Res Commun. 2013 Nov 22;441(3):600-6 - PubMed
  35. Cancer Cell Int. 2015 Oct 24;15:101 - PubMed
  36. J Cell Biol. 2011 Sep 5;194(5):737-50 - PubMed
  37. Exp Ther Med. 2016 Feb;11(2):427-434 - PubMed
  38. Mol Med Rep. 2016 Jun;13(6):5200-6 - PubMed
  39. J Biol Chem. 2013 Aug 9;288(32):23505-17 - PubMed

Publication Types